<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0871-9721</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Imunoalergologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Imunoalergologia]]></abbrev-journal-title>
<issn>0871-9721</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Alergologia e Imunologia Clínica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0871-97212021000300179</article-id>
<article-id pub-id-type="doi">10.32932/rpia.2021.09.064</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Imunoterapia com aeroalergénios em tempos de COVID-19]]></article-title>
<article-title xml:lang="en"><![CDATA[Aeroallergen immunotherapy during COVID-19 pandemic]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cosme]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[Amélia Spínola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Resende]]></surname>
<given-names><![CDATA[Anabela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[Susana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pedro]]></surname>
<given-names><![CDATA[Elisa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar Universitário de Lisboa Norte Hospital de Santa Maria Serviço de Imunoalergologia]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Hospitalar Universitário de Lisboa Norte Consulta Externas Centro de Ambulatório]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>29</volume>
<numero>3</numero>
<fpage>179</fpage>
<lpage>196</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212021000300179&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212021000300179&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0871-97212021000300179&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Fundamentos: A imunoterapia subcutânea a aeroalergénios (ITASC) foi suspensa em alguns serviços durante o confinamento em contexto da pandemia por COVID&#8209;19.  Objetivos: Avaliar o impacto da suspensão da ITASC nos sintomas, necessidade de medicação de controlo e qualidade de vida e, ainda, conhecer as expectativas e grau de segurança/receio dos doentes em voltar ao hospital.  Métodos: Inquérito anónimo para autopreenchimento pelos doentes com mais de 12 anos nas primeiras 5 semanas após reinício da ITASC. Utilizou&#8209;se o CARAT como instrumento de avaliação do controlo dos sintomas de rinite e asma.  Resultados: Incluiram&#8209;se 77 doentes (90% adultos, 68% mulheres), todos com rinite e 40% com asma. O intervalo de tempo médio entre a última administração e o reinício da ITASC foi de 13±2,48 semanas. Foram observados em consulta urgente/não programada por agudização da patologia respiratória 7% dos doentes e apenas 1 teve COVID&#8209;19. As pontuações CARAT&#8209;Total revelaram controlo dos sintomas de rinite e de asma em 35% e 66% dos doentes, respetivamente. A proporção de doentes não controlados aumentou com o alargamento do período de suspensão (PS) da ITASC. A maioria (&gt;90%) dos doentes referiu não haver impacto significativo na sua qualidade de vida e manteve a medicação de controlo habitual (48%), referiu preocupar&#8209;se em perder os benefícios da ITASC com a sua suspensão (62%) e referiu sentir&#8209;se mais seguro nos gabinetes de vacinas do que no edifício do hospital ou sala de espera.  Conclusões: Registou&#8209;se um aumento da frequência de doentes não controlados com o aumento do PS. Para a maioria, o PS não teve impacto significativo na qualidade de vida. A frequência de doentes que necessitaram de ser observados em consulta urgente/não programada foi baixa e apenas 1 referiu ter tido COVID&#8209;19. A perceção de segurança na sala de vacinas é maior do que nos espaços comuns do hospital.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background: Subcutaneous immunotherapy with aeroallergen (SCITA) was stopped in some departments during the lockdown period due to the COVID&#8209;19 pandemic.  Objectives: To evaluate the impact of SCITA interruption on symptoms, the need for control medication, the quality of life, and the expectations and degree of safety / fear of patients on returning to the hospital.  Methods: Self&#8209;completion of an anonymous survey for patients over 12 years in the first 5 weeks of SCITA restart. CARAT was used as an instrument to assess rhinitis and asthma control.  Results: 77 patients (90% adults, 68% women) were included, all with rhinitis and 40% with asthma. The average time interval between the last administration and the restart of SCITA was 13 ± 2.48 weeks. Seven percent of patients were seen in an emergency/unscheduled appointment due to the exacerbation of respiratory symptoms and only 1 had COVID&#8209;19. CARAT&#8209;Total scores showed control of rhinitis and asthma, respectively, in 35% and 66% patients. The proportion of uncontrolled patients rised with the increase in the SCITA interruption period (IP). The majority (&gt; 90%) of patients reported no significant impact on their quality of life and maintained the usual control medication (48%), expressed concern about losing the benefits of SCITA with its interruption (62%) and reported feeling safer in the vaccination offices compared to the hospital building or waiting room.  Conclusions: An increase in the frequency of uncontrolled patients with an increase in IP was observed. For most patients, the IP did not have a significant impact on quality of life. The frequency of patients who needed to be observed in an emergency / unscheduled appointment was low and only 1 reported having had COVID&#8209;19. The perception of safety in the vaccination room is higher than in the hospital&#8217;s common spaces.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Asma]]></kwd>
<kwd lng="pt"><![CDATA[CARAT]]></kwd>
<kwd lng="pt"><![CDATA[COVID&#8209;19]]></kwd>
<kwd lng="pt"><![CDATA[imunoterapia subcutânea a alergénios]]></kwd>
<kwd lng="pt"><![CDATA[medicação]]></kwd>
<kwd lng="pt"><![CDATA[sintomas]]></kwd>
<kwd lng="pt"><![CDATA[qualidade de vida]]></kwd>
<kwd lng="pt"><![CDATA[rinite.]]></kwd>
<kwd lng="en"><![CDATA[Asthma]]></kwd>
<kwd lng="en"><![CDATA[CARAT]]></kwd>
<kwd lng="en"><![CDATA[COVID&#8209;19]]></kwd>
<kwd lng="en"><![CDATA[medication]]></kwd>
<kwd lng="en"><![CDATA[quality of life]]></kwd>
<kwd lng="en"><![CDATA[rhinitis]]></kwd>
<kwd lng="en"><![CDATA[subcutaneous immunotherapy with aeroallergen]]></kwd>
<kwd lng="en"><![CDATA[symptoms.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<source><![CDATA[Diário da República]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Restrição de atividades nas instituições de saúde e proteção individual]]></article-title>
<source><![CDATA[Ordem dos Médicos - Colégio de Imunaolergologia]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ponda]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Creticos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Administration of subcutaneous allergen immunotherapy during the COVID&#8209;19 outbreak: a Work Group Report of the AAAAI Immunotherapy, Allergen Standardization and Allergy Diagnostics (IASAD) Committee 2020]]></article-title>
<source><![CDATA[]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[World Allergy Organization Preparing your office for the COVID&#8209;19 pandemic]]></article-title>
<source><![CDATA[2020]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfaar]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Klimek]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jutel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Akdis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Akdis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Handling of allergen immunotherapy in the COVID&#8209;19 pandemic: An ARIA&#8209;EAACI statement]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2020</year>
<volume>75</volume>
<page-range>1546&#8209;54</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfaar]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Klimek]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jutel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Akdis]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Breiteneder]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID&#8209;19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position paper]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2021</year>
<volume>76</volume>
<page-range>648&#8209;676</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nickels]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tamesis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID&#8209;19&#8217;s impact on allergists&#8217; clinical services and protocols 2020]]></article-title>
<source><![CDATA[American College of Allergy, Asthma and Immunology]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nogueira-Silva]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz&#8209;Correia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Morais-Almeida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bugalho&#8209;Almeida]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control of allergic rhinitis and asthma test - a formal approach to the development of a measuring tool]]></article-title>
<source><![CDATA[Respir Res]]></source>
<year>2009</year>
<volume>10</volume>
<page-range>52</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Nogueira &#8209;Silva]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Morais-Almeida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sá&#8209;Sousa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Branco&#8209;Ferreira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2010</year>
<volume>65</volume>
<page-range>1042&#8209;8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilização conjunta do CARAT e função respiratória na avaliação do controlo da asma e rinite]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2013</year>
<volume>21</volume>
<page-range>103-15</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ricardo Pereira]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudo transversal da avaliação do controlo da rinite e asma alérgicas em consulta hospitalar de Imunoalergologia através do questionário CARAT10]]></article-title>
<source><![CDATA[Rev Port Pneumologia]]></source>
<year>2013</year>
<volume>19</volume>
<page-range>163&#8209;67</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Branco Ferreira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues Alves]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira Barbosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imunoterapia específica: Uma mais&#8209;valia no tratamento da asma e rinite alérgicas]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2009</year>
<volume>17</volume>
<page-range>13&#8209;35</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spínola Santos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Branco Ferreira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira Barbosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imunoterapia específica e controlo da asma]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2012</year>
<volume>20</volume>
<page-range>109&#8209;20</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kakourou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Asamoah]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Agache]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jutel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allergen immunotherapy for allergic asthma: A systematic review and meta&#8209;analysis]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2017</year>
<volume>72</volume>
<page-range>1825&#8209;48</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lombardi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barrocu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Landi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ridolo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bugiani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The control of allergic rhinitis in real life: a multicenter cross&#8209;sectional Italian study]]></article-title>
<source><![CDATA[Clin Mol Allergy]]></source>
<year>2018</year>
<volume>16</volume>
<page-range>4</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verdiani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Di Carlo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Baronti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Different prevalence, and degree of non&#8209;specific bronchial hyperreactivity between seasonal and perennial rhinitis]]></article-title>
<source><![CDATA[J Allergy Clin lmmunol]]></source>
<year>1990</year>
<volume>86</volume>
<page-range>576&#8209;78</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaaban]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zureik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soussan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Antó]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Heinrich]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Janson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Allergic rhinitis and onset of bronchial hyperresponsiveness: a population&#8209;basedstudy]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2007</year>
<volume>176</volume>
<page-range>659&#8209;66</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cirillo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vizzaccaro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tosca]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Negrini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Negrini]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Marseglia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bronchial hyperreactivity and spirometric impairment in patients with allergic rhinitis]]></article-title>
<source><![CDATA[Monaldi Arch Chest Dis]]></source>
<year>2005</year>
<volume>63</volume>
<page-range>79&#8209;83</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braman]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Barrows]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[DeCotiis]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Settipane]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Corrao]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Airway hyperresponsiveness in allergic rhinitis. A risk factor for asthma]]></article-title>
<source><![CDATA[Chest]]></source>
<year>1987</year>
<volume>91</volume>
<page-range>671&#8209;4</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Stebbing]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Parronchi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Farsi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is asthma protective against COVID&#8209;19]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2021</year>
<volume>76</volume>
<page-range>866&#8209;8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morais&#8209;Almeida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pité]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Aguiar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ansotegui]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asthma and the coronavirus disease 2019 pandemic: A literature review]]></article-title>
<source><![CDATA[Int Arch Allergy Immunol]]></source>
<year>2020</year>
<volume>181</volume>
<page-range>680&#8209;8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guyatt]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Oxman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Vist]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Kunz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Falck&#8209;Ytter]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso&#8209;Coello]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2008</year>
<volume>336</volume>
<page-range>924&#8209;6</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pulvirenti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cinetto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Milito]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bonanni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pesce]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Leodori]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health&#8209;related quality of life in common variable immunodeficiency italian patients switched to remote assistance during the COVID&#8209;19 pandemic]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2020</year>
<volume>8</volume>
<page-range>1894&#8209;9.e2</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Passalacqua]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Baiardini]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Senna]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Canonica]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis]]></article-title>
<source><![CDATA[Clin Exp Allergy]]></source>
<year>2013</year>
<volume>43</volume>
<page-range>22&#8209;8</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pfaar]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Akdis]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Ansotegui]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Durham]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Gerth van Wijk]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EAACI Guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2018</year>
<volume>73</volume>
<page-range>765&#8209;98</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
